Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel followed by FEC with gene-expression profiling in primary breast cancer
2008-006381-29Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- Jun 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, fluorouracil, epirubicin and cyclophosphamide in breast cancer, sponsored by University Medical Center Mainz. Primary endpoint: Predictive gene expression signature for pathological complete response. Started Jun 2009; status: completed.
02
Drugs
docetaxelfluorouracilepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-006381-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006381-29.